A Form 483 lists what FDA investigators saw, not the agency's verdict
ON THIS PAGE
Key findings
- FDA issues a Form 483 to a firm's management at the end of an inspection, and says it "does not constitute a final Agency determination" of any violation.
- FDA's inspection manual tells investigators not to call conditions "violative" on the form. That call is the agency's, made later.
- A 2009 FDA notice says replies received within 15 business days of a 483 are reviewed in detail before FDA decides on a warning letter.
- Not every 483 is made public. FDA's reading room posts one when the public interest warrants it, or when three or more people have asked for it.
- In the Empower Pharmacy case, the 483 issued on November 14, 2025 and the warning letter is dated September 18, 2026, 308 days later.
An FDA inspection ends with a sheet of paper. It is Form FDA 483, "Inspectional Observations," and the investigators hand it to the firm's management before they leave.
The form is a list of what they saw. It is not a ruling. FDA's own question-and-answer page says so in plain terms: the form "does not constitute a final Agency determination of whether any condition is in violation." A warning letter, if one comes, is a separate document written later. The warning letter explainer covers that second step.
What is a Form 483?
It is a written notice of problems found during an inspection. FDA's page "FDA Form 483 Frequently Asked Questions" (content current as of January 9, 2020, read October 17, 2026) says the form "is issued to firm management at the conclusion of an inspection." It goes out when investigators have seen conditions that may break the Food, Drug, and Cosmetic Act or related laws.
The same page says each observation is read aloud to management at the end of the inspection.
The form is also not a full list. FDA says it leaves out "observations of questionable or unknown significance." A firm is still expected to fix related problems that were never written down.
Who writes it, and what they may put on it
The investigators who did the inspection write and sign it. The rules are in Chapter 5 of FDA's Investigations Operations Manual (2022 edition, read October 17, 2026). Section 5.2.3.1.2 says everyone present under FDA inspection authority at issuance signs the first and last pages and initials the pages between.
Section 5.2.3 says the form notifies "top management in writing of significant objectionable conditions" seen during the inspection. Those observations rest on the investigator's "judgment." The manual says issuing them in writing "is mandated by law and ORA policy."
The manual sets a firm limit on what the form may say. Section 5.2.3.3 reads: "Do not report opinions, conclusions, or characterize conditions as 'violative.'" Whether a condition is a violation "is an agency decision made after considering all circumstances, facts and evidence." Departures from guidance documents are not cited on the form either.
This is the line a reader most needs. A 483 records facts as the investigator saw them. The legal judgment comes afterwards, from the agency, and it can go either way.
How a firm answers a 483
A firm can answer on the spot and in writing later. On the spot, section 5.2.3.4 of the manual lets the investigator annotate each observation if the firm agrees. Annotation is voluntary for the firm, and the manual says the investigator must honor a refusal. The four approved notes are "Reported corrected, not verified," "Corrected and verified," "Promised to correct," and "Under consideration." A firm's objections are not written on the form; they go in the investigator's report instead.
In writing, FDA's FAQ page says firms "are encouraged to respond to the FDA Form 483 in writing with their corrective action plan." Timing matters. FDA's notice "Review of Post-Inspection Responses" (74 Fed. Reg. 40211, August 11, 2009, read on govinfo.gov October 17, 2026) set the clock. For a reply received "within 15 business days after the FDA 483 was issued," FDA said it would review the reply in detail before deciding whether to issue a warning letter. For later replies, it said it would not routinely judge the fixes in a warning letter. The program began on September 15, 2009.
The stake is plain. A late reply can mean a warning letter that does not mention the fixes a firm has already made.
What FDA does after the 483
The agency weighs more than the form. FDA's FAQ page says it considers the 483, the Establishment Inspection Report (the investigators' full written account), the evidence collected on site, and the firm's replies. Then it decides whether to act.
Each inspection is then given a class. FDA's Inspection Classification Database page (content current as of September 13, 2024, read October 17, 2026) lists three. No Action Indicated means the facility was in an acceptable state of compliance. Voluntary Action Indicated means objectionable conditions were found, but FDA will not recommend action and expects the firm to fix them on its own. Official Action Indicated means an unacceptable state of compliance. The page says final classification letters usually reach the firm 45 to 90 days after an inspection closes, and that inspections still awaiting final enforcement action are left out of the database.
So a 483 can end in no action at all.
Where 483s become public
Not all of them do. FDA's OII FOIA Electronic Reading Room page (content current as of October 6, 2026, read October 17, 2026) says: "Not all inspectional observations (Form FDA 483s) or Establishment Inspection Reports (EIRs) are publicly posted."
The page names two routes. FDA may post a record on its own when "the public has a meaningful interest in the information." It also posts records that "three or more people or organizations have separately requested" under the Freedom of Information Act. Records that meet neither route "will not appear here, even if an inspection took place." Posted copies may be partly blacked out to protect trade secrets, confidential business information and personal information.
A missing 483 proves nothing. It does not mean no inspection, or a clean one.
How the sequence reads in a posted letter
A warning letter that follows an inspection can date every step. The September 18, 2026 letter to Empower Clinic Services, LLC dba Empower Pharmacy (MARCS-CMS 738238, content current as of September 22, 2026, read October 17, 2026) is one example, covered in this publication's report on that letter.
- Inspection: the letter says FDA inspected the firm "From November 3, 2025, through November 14, 2025."
- Form 483: "FDA issued a Form FDA 483 to your firm on November 14, 2025."
- Replies: FDA acknowledged responses "dated December 8, 2025, March 18, 2026, and April 30, 2026." The first came 24 days after the 483.
- Letter: dated September 18, 2026, 308 days after the 483. It asks for a reply "Within fifteen (15) working days of receipt of this letter."
The letter also shows the agency judging the replies. It states that FDA reviewed the firm's response to the Form FDA 483, and that some corrective actions "appear adequate" while others "appear deficient." That is the second look the 483 itself is not allowed to give.
Limitations
This piece reads FDA's manuals and pages as the agency's account of its own practice, not as law. The manual chapter read here is the 2022 edition, and the reply-timing notice dates from 2009; FDA may have changed either since without the change appearing on the pages read. One worked example cannot show how often a 483 leads to a letter, and no FDA source read here gives that figure. Nothing here describes Empower Pharmacy beyond what its posted letter says.
A 483 opens the record. What the agency makes of it shows up later, if it shows up at all.
Sources
All read 2026-10-17. FDA Form 483 Frequently Asked Questions, content current as of 2020-01-09. Investigations Operations Manual 2022, Chapter 5, Establishment Inspections, sections 5.2.3, 5.2.3.1.2, 5.2.3.3 and 5.2.3.4. Review of Post-Inspection Responses, Food and Drug Administration, 74 Fed. Reg. 40211 (August 11, 2009), FR Doc. E9-19107, read on govinfo.gov. Inspection Classification Database, content current as of 2024-09-13. OII FOIA Electronic Reading Room, content current as of 2026-10-06. Empower Clinic Services, LLC dba Empower Pharmacy, MARCS-CMS 738238, dated September 18, 2026, content current as of 2026-09-22.
Email updates
New articles and news by email, at most once a day or once a week, whichever you pick.
Respond to this analysis
Corrections, contradictions, and anything you have seen yourself. Responses are read and checked. Verified ones become entries in the ledger or corrections to this page. Nothing posts unverified, and no response is published with anything but the handle you type, or the display name of the account you sign in with. Reporting an error, or asking for this article to come down? Use the Report form below.
Report an error or request a takedown
Reports go to the site's administrators. Nothing is removed automatically.